ūüďě  +1 (855) 661-4441(US)   ūüďě  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Anal Cancer Market Research Report Information by Cancer Type (Carcinoma in Situ, Squamous Cell Carcinoma, Adenocarcinoma, Basal Cell Carcinoma, Melanoma and others), Treatment Type (Chemotherapy, Surgery, Radiation Therapy and Immunotherapy), End User (Hospitals & Clinics, Research & Academic Institutes and others) - Forecast till 2032

ID: MRFR/MED/1001-HCR | 130 Pages | Author: Kinjoll Dey| July 2024

Global Anal Cancer Market Overview

Anal Cancer Size was valued at USD 0.96 Billion in 2023. The Global Anal Cancer industry is projected to grow from USD 1.01 Billion in 2024 to USD 1.78 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.73% during the forecast period (2024 - 2032).Anal cancer is a rare type of cancer that begins in the anus, which is the orifice at the rectum's end. Anal cancer has one of the highest rates of occurrence and prevalence in the globe. Lifestyle issues, aging, and diet are thought to be the primary causes of anal cancer. According to the World Health Organization (WHO), an increase of roughly 70% in anal cancer cases is projected globally over the Anal Cancer Market Analysis period.

Squamous cell carcinoma, which develops from cells around or in the anal entrance or, in rare cases, in the anal canal, is the most common type of anal cancer. This malignancy is frequently linked to the human papillomavirus (HPV), with HPV malignancies or cervical cancers having a significant chance of progressing to anal cancer. Anal cancer has no specific symptoms, however, it might cause bleeding from the anal area, a tumor or swelling near the anus, or a change in bowel habits. Tumor, node, and metastasis are divided into I, II, IIIA, IIIB, and IV stages, which are further divided into I, II, IIIA, IIIB, and IV. Melanoma, adenocarcinoma, basal cell carcinoma, and gastrointestinal stromal tumor (GIST) are the main types of anal cancer, and most people with anal cancer are treated with chemoradiation, which is a mix of chemotherapy and radiation. Combining therapy raises the likelihood of a successful cure and is expected to grow during the Anal Cancer Market Forecast period.

Darmstadt, June 2024 – Merck announced it had made significant progress in its cancer drug development portfolio, including the Phase II trials of tuvusertib (an ATR inhibitor) and M9466 (a PARP1 inhibitor). In addition to these, Merck has taken M9140 (anti-CEACAM5 ADC) and M3554 (novel anti-GD2 ADC) into the clinical stage. Merck’s broader oncology strategy is also using such synergistic approaches as the two focus areas include - antibody drug conjugates or ADCs; DNA damage response inhibitors or DDR inhibitors; and next-generation immunotherapy compounds.

Indianapolis, June 2024 – Eli Lilly revealed positive findings from an early-stage trial of olomorasib, which is a second-generation KRAS G12C inhibitor with activity observed against various solid tumors involving KRAS G12C mutations, including non-small cell lung cancer. This has been combined with KEYTRUDA® (pembrolizumab), a PD-1 inhibitor manufactured by Merck, which has shown good tolerability when used together with olomorasib in another study.

April 2024 – The FDA approved Enhertu (trastuzumab deruxtecan) as the first HER2-directed therapy indicated for use in patients with unresectable or metastatic HER2-positive solid tumors based on three phase II trials showing meaningful responses across multiple tumor types. Thus, Enhertu’s versatility may be further reinforced through expedited endorsement to serve as a therapy option for HER2 patients who have exhausted other treatments.

In November 2023, Eli Lilly, an American pharmaceutical company, announced that it plans to build another plant in western Germany worth around €2bn ($2.17bn).

For example, this was demonstrated in September 2023 when Ride Cincinnati Cancer Research Organization partnered with University of Cincinnati Cancer Center Research to raise $4 million for anal cancer patients and improve of the life quality of patients. It means that their increased research activities that have aimed at identifying causes and remedies for this disease have boosted this market’s expansion rates.

In August 2023, Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced the FDA approval of LONSURF® (trifluridine/tipiracil), which indicated its usage in adults with metastatic colorectal cancer (mCRC). These include anti-VEGF biological therapy, fluoropyrimidine, oxaliplatin, or irinotecan-containing chemotherapy beforehand, and also, if RAS wild-type, an anti-EGFR therapy after all.

June 2023: AstraZeneca and Daiichi Sankyo presented positive results from clinical study of the DESTINY CRC02 phase trial for Enhertu, including efficacy as well as safety information among patients who had previously been treated for HER-2 overexpressing metastatic colorectal cancer.

In October 2022 alone, American Cancer Society awarded a total cost of $54.3M to fund the recently established extramural discovery science projects covering 89 cases, thereby facilitating researchers working under these grants throughout the year starting January 1st, 2023 across sixty-five institutions in the US.

In June 2021, Bristol Myers Squibb received European Commission approval for Opdivo plus Yervoy to treat anal cancer patients; therefore, it has received marketing authorizations all over Europe.

COVID Analysis

The COVID-19 epidemic has wreaked havoc on healthcare systems around the world, as well as the anal cancer industry. Cancer screening and other health prevention services, as well as elective surgeries, should be postponed unless the risks outweighed the benefits, according to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations, to secure the hospital infrastructure for the treatment of COVID-19 patients. As a result, the COVID-19 pandemic has influenced ongoing clinical trials. The situation, though, is likely to progressively improve and increase Anal Cancer Market Growth. COVID-19 has resulted in a significant increase in demand for ventilators, in contrast to market Growth, and manufacturers are currently focusing their efforts on satisfying the increased need for ventilators, as well as other types of equipment. The high rate of sexual intercourse is expected to grow and increase Anal Cancer Market Outlook.

Anal Cancer Market Trends


Anal Cancer Market Value is predicted to be fueled by factors such as the rising prevalence of anal cancer and the rising number of sexually transmitted illnesses. An anticipated 8,300 additional cases of anal cancer were detected during the historical prediction period, according to a report released by the American Cancer Society. Females are responsible for around 5,530 of these incidents. In the last several years, the number of cases of anal cancer has increased. There will be approximately 9,090 new cases in the United States. Anal cancer is uncommon in those under the age of 35 and is mostly diagnosed in older adults, with an average age in the early 60s. Furthermore, growing oncology research and development spending are likely to promote Anal Cancer Market Trends. The government's increasing initiatives to raise public awareness about anal malignancies are the primary drivers of the market.

Anal cancer is a type of cancer that affects the colon and rectum. The income earned by medications used to treat anal cancer, as well as other screening tests, kits, and medical devices used to diagnose colorectal cancer, is tracked in the study. The high spending on public health initiatives, as well as the rapid rise in global healthcare expenditure and research and development expenditure in the field of oncology, are projected to provide substantial potential prospects and increase the market size.


However, the treatment's negative effects and a lack of knowledge are projected to stifle Anal Cancer Market Trends. The market's expansion is projected to be hampered by high treatment costs. According to the American Cancer Society, the cost of anal cancer treatment in India ranges from USD 1500 to USD 15,000, which is a significant burden for emerging and impoverished countries. One of the primary reasons limiting market Share is this. Inadequate reimbursement and a scarcity of competent experts, on the other hand, may limit the market value.

Anal Cancer Market Segmentation

Anal Cancer Type Outlook

  • Carcinoma In Situ

  • Squamous Cell Carcinoma

  • Melanoma

  • Adenocarcinoma

  • Basal Cell Carcinoma

  • Others

Anal Cancer treatment type Outlook

Anal Cancer end-user Outlook 

  • Hospitals & Clinics

  • Research & Academic Institutes

  • Others

Anal Cancer Market Regional Classification


The Americas are likely to lead the anal cancer market because of the increased prevalence of anal cancer. According to the American Cancer Society, around 1,280 persons will die of anal cancer during the forecast period.

Europe is predicted to represent the second-largest share of the anal cancer market because of the increased prevalence of anal cancer and the presence of significant market participants. During the historic forecast period, 1,438 new cases of anal cancer were discovered in the UK, according to Cancer Research UK.

Asia-Pacific is predicted to be the fastest-growing regional market due to expanding cancer awareness and the incidence of sexually transmitted illnesses.

In The Middle East and Africa, due to the high incidence rate of anal cancer, the market is likely to develop gradually throughout the forecast period.



  • North America

    • US

    • Canada

  • Latin America


  • Western Europe

    • Germany

    • France

    • Italy

    • Spain

    • UK

  • Rest of Western Europe

  • Eastern Europe


  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific

The Middle East & Africa

  • Middle East

  • Africa

Anal Cancer Market Competitive Landscape

Due to the presence of many small and large market players, the industry analyzed is fairly consolidated. Furthermore, several new biotech companies are entering the therapeutics market by releasing new drugs and collaborating and acquiring other companies in the global anal cancer market. 

  • Amgen Inc. (US)

  • Eli Lilly and Company (US),

  • Bristol-Myers Squibb Company (US)

  • Merck & Co., Inc. (the US)

  • Novartis AG (Switzerland)

  • Celgene Corporation (US)

  • Pfizer Inc. (US)

  • Sanofi (France)

  • GlaxoSmithKline plc (UK)

  • Johnson & Johnson Services, Inc. (the US)

  • F. Hoffmann-La Roche Ltd (Switzerland)

  • Hospira, Inc. (the US)

Recent Developments

The Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not with Atezolizumab in Patients with Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma, which Roche Pharma AG is conducting.

Hoffmann-La Roche Ltd develops cutting-edge medications and diagnostic tests that benefit millions of people across the world. Roche was one of the first pharmaceutical corporations to provide patients with targeted therapy. They are more suited than any other company to advance personalized healthcare due to their combined strength in drugs and diagnostics.

Report Overview

The study highlights the important commercial assets and players in the Anal Cancer Market segmentation by Cancer type, Treatment type, End-users, and geography. It also analyses trends and co-development arrangements to identify business opportunities in the market. The report contains the most up-to-date analysis, which was compiled after conducting extensive qualitative interviews and doing a thorough market analysis. This report also includes information on market drivers, restraints, new product launches or approvals, market trends, regional outlooks, and key players' competitive strategies. Company overview, financial performance, product portfolio, market presence, distribution strategies, important advancements, strategies, and plans are used to profile key players in the global market.

Report Attribute/Metric Details
  Market Size  USD 1.78 Billion (2024-2032)
  CAGR   8.73% (2024-2032)
  Base Year   2023
  Forecast Period   2024-2032
  Historical Data   2022
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Information by Cancer Type, Treatment Type, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Sanofi (France), Johnson & Johnson Services, Inc. (US) and Hospira, Inc. (US)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers ·  Rising prevalence of anal cancer ·  The growing number of sexually transmitted diseases

Frequently Asked Questions (FAQ) :

Anal cancer market valuation was USD 1.78 Billion

Anal cancer market CAGR would be 8.73% during the forecast period.

Anal cancer market top players are Celgene Corporation (US), Amgen Inc. (US), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lilly and Company (US), Pfizer Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Sanofi (France), Johnson & Johnson Services, Inc. (US,) GlaxoSmithKline plc (UK), and Hospira, Inc. (US)

Anal cancer market in the Americas would be the largest.

The Asia Pacific region would be the fastest-growing region for anal cancer market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.